The FDA is reviewing information to determine the safety of Xolair.
Press Release Service – Wired PR News – Information about the asthma medication Xolair, has recently been placed under review by the Food and Drug Administration (FDA). As reported by the Associated Press (AP), Xolair, which was placed on the market in 2003, may possibly be linked to serious health issues, according to preliminary data from a study on 5,000 patients who took the medication.
As noted in the report, taken through injection, the drug, created by Swiss pharmaceutical company Novartis, was initially approved by the FDA to treat people ages 12 and up who suffer from moderate to severe asthma that cannot be controlled by inhalants. Recent data proposes that Xolair can increase the chances of fatal conditions such as stroke or heart attack.
Tara Cooper, a spokesperson for Swiss drugmaker Genetech, is quoted by the AP as stating, “At this time there is insufficient information for the companies to change their assessment of the benefit-risk profile for Xolair.”
WiredPRNews.com – The latest in Health News.